Sugi Predict

Sugi Predict / Compounds / SCHEMBL345306

SCHEMBL345306

SCHEMBL345306

CC(C)(C)OC(=O)N1CC[C@H](CC(=O)O)C1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.49
▸ PKM P14618 1/20 0.49
▸ NR1H2 P55055 1/20 0.48
▸ HPGD P15428 1/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ GLS O94925 3/20 0.45
▸ GPR119 Q8TDV5 1/20 0.45
▸ RECQL P46063 1/20 0.44
▸ EPHX1 P07099 1/20 0.44
▸ JAK2 O60674 1/20 0.44
▸ JAK1 P23458 1/20 0.44
▸ IDO1 P14902 1/20 0.43
▸ TDO2 P48775 1/20 0.43
▸ USP30 Q70CQ3 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL874037 1.00 KDM4E (0.49) KDM4EPKMNR1H2HPGDMEN1
SCHEMBL345307 1.00 KDM4E (0.49) KDM4EPKMNR1H2HPGDMEN1
SCHEMBL1225792 0.91 GLS (0.54) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL2461387 0.91 GLS (0.54) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL1225791 0.91 GLS (0.54) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL584378 0.90 KDM4E (0.54) KDM4EPKMNR1H2HPGDMAPT
SCHEMBL28589778 0.90 KDM4E (0.47) KDM4EPKMNR1H2HPGDALDH1A1
SCHEMBL28589780 0.90 KDM4E (0.47) KDM4EPKMNR1H2HPGDALDH1A1
SCHEMBL30922794 0.90 GLS (0.50) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL28063864 0.89 KDM4E (0.53) KDM4EPKMNR1H2HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747232-A1 PYRROLIDINE COMPOUNDS WITH LP(A) LOWERING ACTIVITY Eli Lilly and Company (US) 2026-05-27 — — EP disclosed
CN-117177975-B Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof 蒙特利尔大学 2026-05-19 — — CN disclosed
US-20260124214-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2026-05-07 — — US disclosed
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 — — WO disclosed
US-12583839-B2 PD-L1 antagonist compound ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2026-03-24 — — US disclosed
EP-4711355-A1 CRYSTAL FORM OF LIPOPROTEIN COMPOUND AND PREPARATION METHOD THEREFOR Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2026-03-18 — — EP disclosed
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 — — US disclosed
WO-2025262297-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 DARK BLUE THERAPEUTICS LTD (GB) 2025-12-26 — — WO disclosed
US-12441714-B2 Pyrrolidine compounds ELI LILLY AND COMPANY (US) 2025-10-14 — — US disclosed
EP-4419525-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2025-07-23 — — EP disclosed
US-20090062251-A1 Novel Compounds 002 ASTRAZENECA AB (SE) 2009-03-05 — — US disclosed
US-20090062251-A1 Novel Compounds 002 ASTRAZENECA AB (SE) 2009-03-05 — — US disclosed
US-20090062251-A1 Novel Compounds 002 ASTRAZENECA AB (SE) 2009-03-05 — — US disclosed
WO-2009024819-A1 CANNABINOID RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2009-02-26 — — WO disclosed
WO-2009024819-A1 CANNABINOID RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2009-02-26 — — WO disclosed
US-20080269288-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2008-10-30 — — US disclosed
WO-2008053194-A2 PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS ASTRAZENECA AB (SE) 2008-05-08 — — WO disclosed
US-20070208056-A1 PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2007-09-06 — — US disclosed
WO-2007092681-A2 PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2007-08-16 — — WO disclosed
US-5726185-A BINDING OF ADHESIVE PROTEINS TO BLOOD PLATELET AGGREGATION AND CELL TO CELL ADHESION HOFFMANN-LA ROCHE INC. (US) 1998-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062251-A1 Novel Compounds 002 OPRL1, OPRK1, OPRM1 KDM4E 2054/4885PKM 950/4885NR1H2 243/4885
US-20260124214-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CBR1, NR3C1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 KDM4E 3258/4885PKM 3381/4885NR1H2 33/4885
US-20070208056-A1 PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCR1, CCR2, CCR3 KDM4E 4438/4885PKM 3394/4885NR1H2 243/4885
US-20080269288-A1 CHEMICAL COMPOUNDS HSD11B1, CYP11B1, CYP4A11 KDM4E 2034/4885PKM 1452/4885NR1H2 92/4885
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF NSUN3, BCAT1, SLC43A1 KDM4E 671/4885PKM 3635/4885NR1H2 2746/4885
US-12441714-B2 Pyrrolidine compounds ADCYAP1R1, AVPR2, NPPA KDM4E 1657/4885PKM 227/4885NR1H2 3714/4885
US-12583839-B2 PD-L1 antagonist compound CD274, PDCD1LG2, PDCD1 KDM4E 2998/4885PKM 3685/4885NR1H2 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.